The aberrant activation of tyrosine kinases represents an important oncogenic mechanism, and yet the majority of such events remain undiscovered. Here we describe a bead-based method for detecting phosphorylation of both wild-type and mutant tyrosine kinases in a multiplexed, high-throughput and low-cost manner. With the aim of establishing a tyrosine kinase-activation catalog, we used this method to profile 130 human cancer lines. Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo. Testing of dasatinib-resistant tyrosine kinase alleles confirmed that SRC is indeed the relevant target of dasatinib, which inhibits many tyrosine kinases. These studies establish the feasibility of tyrosine kinome-wide phosphorylation profiling and point to SRC as a possible therapeutic target in glioblastoma.
The aberrant activation of tyrosine kinases represents an important oncogenic mechanism, and yet the majority of such events remain undiscovered. Here we describe a bead-based method for detecting phosphorylation of both wild-type and mutant tyrosine kinases in a multiplexed, high-throughput and low-cost manner. With the aim of establishing a tyrosine kinase-activation catalog, we used this method to profile 130 human cancer lines. Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo. Testing of dasatinib-resistant tyrosine kinase alleles confirmed that SRC is indeed the relevant target of dasatinib, which inhibits many tyrosine kinases. These studies establish the feasibility of tyrosine kinome-wide phosphorylation profiling and point to SRC as a possible therapeutic target in glioblastoma.
All tumors, regardless of their cell of origin, arise through the aberrant activation of oncogenic pathways. Foremost among oncogenes discovered to date are the tyrosine kinases, which are receiving high priority in international efforts to systematically discover all recurrent genomic alterations in the cancer genome. Although such cancer genome efforts will certainly identify mutations in tyrosine kinaseencoding genes, there is mounting evidence of indirect, oncogenic activation of kinases. For example, the platelet-derived growth factor receptor (PDGFR)-b is aberrantly activated through a chromosomal translocation that results in constitutive expression of its ligand, PDGF-b 1 . Similarly, hepatocyte growth factor (HGF) amplification has been proposed to lead to oncogenic activation of its receptor MET 2 . Such indirect mechanisms of tyrosine kinase activation would not be detected by cancer genome resequencing approaches that focus on the kinases themselves. We therefore sought to develop a method capable of systematically identifying activated tyrosine kinases regardless of the mechanism of activation.
Because nearly all tyrosine kinases become tyrosine phosphorylated after activation, we used tyrosine kinase phosphorylation state as a surrogate for kinase activity. First, we profiled tyrosine phosphorylation in five cell lines using phosphotyrosine peptide immunoprecipitation followed by mass spectrometry (Fig. 1a and Supplementary Table 1 online). We recovered known tyrosine phosphorylated tyrosine kinases and the identities of specific phosphotyrosine sites in these proteins (e.g., ABL1 in K562 harboring a BCR-ABL1 translocation) (Supplementary Table 1 ). However, this mass spectrometrybased approach required large numbers of cells (B10 8 per sample) and many days of sample preparation, processing and instrument time per sample, and was therefore costly (B$1,000 per sample). In addition, its sensitivity depends on the physical characteristics of the phosphopeptides. Thus, it is not well suited to the high-throughput profiling that would be required to capture the diversity of tyrosine kinase activation events in human cancer.
We therefore developed an alternative method based on multiplexed coupling of kinase-specific antibodies to polystyrene microspheres (beads). Tyrosine kinase-specific antibodies are coupled to the beads, with a different bead color for each kinase. Whole protein lysates from cancer lines or patient samples are mixed with the antibody-coupled beads in a multiplexed reaction and then combined with a biotinylated anti-phosphotyrosine antibody that labels all tyrosine-phosphorylated tyrosine kinases in the mixture. Finally, the bead complexes are detected with a Luminex flow cytometer. We used this approach to profile the tyrosine phosphorylation status of 62 of the 90 tyrosine kinases in the human genome (Fig. 1a) , including 4 pseudokinases (ERBB3, EPHB6, PTK7 and RYK), which lack intrinsic kinase activity.
We assessed the performance characteristics of the method by subjecting 46 of the antibodies to further experimental measures of sensitivity and specificity, including the treatment of cells with kinaseactivating ligands, blocking antibodies or overexpression of tyrosine kinase-encoding expression constructs (Supplementary Tables 2-4 online). Of the 46 characterized kinases, 46 (100%) yielded the expected signals, although in some cases the testing of multiple antibodies was required to obtain a properly functioning assay (Fig. 1b, Supplementary Tables 2-4 , Supplementary Methods and Supplementary Fig. 1 online) . Additional experiments were carried out to determine the method's reproducibility, addressing both technical and biological variation. The level of technical variability was very low, ranging from 3-11% ( Fig. 1c and Supplementary Table 5 online). As expected, variability increased when biological replicates were assessed (ranging from 9-35%, Fig. 1c and Supplementary Table 5 ). Based on antibody-specific background levels, we chose threefold over background to represent significant phosphorylation ( Supplementary Fig. 2 online) .
With a robust assay in hand, we initiated the establishment of a resource of tyrosine kinase phosphorylation data for diverse human cancers by profiling 130 human cancer cell lines ( Fig. 2a and Supplementary Table 6 online). As expected, most cell lines showed only a limited repertoire of phosphorylation events. A few kinases (e.g., LCK, LYN, SRC, EGFR, FGFR3 and PTK2) were phosphorylated in many cell lines. The method detected expected patterns of tyrosine phosphorylation, such as ABL1 phosphorylation in K562 cells (chronic myelogenous leukemia cells with a BCR-ABL1 translocation) 3 and KIT phosphorylation in GIST882 cells (gastrointestinal stromal tumor cells with an activating KIT mutation) 4 . Other known examples include MET activation in SNU-5 cells (gastric cancer cells with the MET amplification) 5 and H2009 cells (lung cancer cells with constitutive MET phosphorylation) 6 ; EGFR in HCC827 and HCC4006 cells (lung cancer cells with EGFR exon19del mutant) 7 ; ERBB3 in MDAMB453 cells (breast cancer cells with constitutive ERBB3 phosphorylation) 8 ; FGFR2 in KATOIII cells (gastric cancer cells with FGFR2 amplification) 9 ; and IGF1R in Huh7 (hepatocellular cancer cells in which increased expression and secretion of IGF2 leads to constitutive IGF1R activation) 10 . These results suggest that our bead-based method identifies activated tyrosine kinases regardless of their mechanism of activation.
In its current configuration, the method assays 62 of the 90 human tyrosine kinases, requires limited numbers of cells (B10 5 ), is amenable to high-throughput studies performed in 96-well plates, is inexpensive (B$10 per assay) and has a sensitivity and specificity similar to those of conventional immunoprecipitation-western blotting approaches. The majority of tyrosine-phosphorylated tyrosine kinases that we identified by mass spectrometry were also identified by the bead assay, but some events were missed by one method or the other (Fig. 2b) . The low number of input cells (1,000-fold less than that required for mass spectrometry), together with its low cost and high-throughput format, may make the bead assay a favored method for screening applications. As with any antibody-based assay, however, the quality of the results is primarily determined by the specificity and sensitivity of the capture antibodies. The bead assay should be distinguished from reversed-phase protein microarrays 11 A biotinylated phosphotyrosine antibody and streptavidin Rphycoerythrin conjugate (SAPE) were added sequentially to bind to the phosphotyrosine residues. The mixture was analyzed with a Luminex 100 instrument, whereby each microsphere is analyzed with two lasers-one to detect the bead color and thereby the identity of the tyrosine kinase, and the other to detect the R-phycoerythrin signal reflecting the tyrosine phosphorylation levels on the bead. The right panel presents the IP-MS approach. Total protein lysates were subjected to enzymatic digestion. Subsequently, the digested lysates were immunoprecipitated with a cocktail of phosphotyrosine antibodies to enrich for phosphotyrosine-containing peptides. Upon elution, the peptide mixture was analyzed with MS to determine their sequences and phosphorylation sites. of cells, but, in contrast to the multiplexed assay described here, each analyte (such as a kinase) must be studied one at a time, substantially limiting throughput. In addition, lysate arrays require phospho-specific kinase antibodies, whereas our assay uses nonphospho-specific kinase antibodies with a secondary antiphosphotyrosine antibody, making it applicable to any kinase for which a primary antibody exists.
To determine the feasibility of using our kinase profiling method to discover new targets for cancer therapy, we followed up on one finding from our cell line screen, namely, the frequent activation of SRC in glioblastoma, a particularly devastating type of brain tumor (Fig. 2a) 12 . We confirmed SRC phosphorylation by immunoprecipitation and western blot analysis (Supplementary Fig. 3a and Supplementary Methods online) and documented that the phosphorylation signal is derived from the SRC kinase domain (pY419, reflecting the active SRC conformation), rather than simply being part of a multi-protein complex containing other tyrosine-phosphorylated proteins (Fig. 1b) .
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positive by immunohistochemistry, consistent with the Luminex assay results ( Fig. 2d and Supplementary Table 8 online) . Taken together, these results indicate that SRC activation is a common event in GBM. In cancer, in general, however, SRC mutations are exceedingly rare. In particular, the initial Cancer Genome Atlas effort has yet to identify focal SRC amplification or somatic missense mutations 15 . This further emphasizes the value of functional profiling methods for detecting kinase activation in the absence of kinase mutations.
To determine whether SRC inhibition might be of therapeutic value, we tested the effects of the SRC inhibitor dasatinib on a panel of 71 cancer cell lines. Dasatinib 16 is an ATP-competitive inhibitor initially developed as an ABL inhibitor (for the treatment of chronic myelogenous leukemia (CML)) but which is known to also potently inhibit SRC and other kinases. Thirty out of seventy-one cell lines exhibited an effector concentration for half-maximum response (EC 50 ) o 1 mM using a viability assay (Fig. 3a and Supplementary Table 9 online). Nearly all the cell lines tested displayed decreased 5-bromodeoxyuridine (BrdU) incorporation upon dasatinib treatment, reflecting decreased proliferation ( Fig. 3a and Supplementary Table 9 ). Dasatinib also induced apoptosis in a subset of the cell lines tested ( Fig. 3a and Supplementary Table 9 ). Furthermore, dasatinib inhibited cell migration in a transmembrane assay, consistent with SRC's documented role in cell motility 17 . Although the effects varied among cell lines ( Fig. 3a and Supplementary Table 9 ), dasatinib consistently inhibited GBM cell migration, even in cells where no growth inhibitory effect was observed, consistent with prior studies suggesting a role for SRC in the invasion of glioblastoma cells [18] [19] [20] . Next, we studied the effects of dasatinib in a U87MG cell line-based orthotopic xenograft model of GBM that has been extensively validated 21 . In vivo tumor growth was not affected by treatment with vehicle or the control inhibitor imatinib but was significantly attenuated by treatment with dasatinib (Fig. 3b) .
These results, although preliminary, further support the notion that the SRC activation discovered with our bead assay represents a therapeutic target in GBM. Recent studies have indicated that dasatinib is a potent inhibitor of many tyrosine kinases. Specifically, 20 tyrosine kinases have a K d o 1 nM in a biochemical assay of kinase inhibition 22 . It is therefore plausible that the dasatinib effects observed in GBM might be attributable to tyrosine kinases other than SRC. To address this issue, we generated dasatinib-resistant alleles of candidate kinases and tested them for their ability to rescue the dasatinib effects observed in GBM cells. To make the dasatinibresistant mutants, we exploited the observation that all dasatinibtargeted kinases contain a conserved threonine ('gatekeeper') in the kinase domain. This threonine is essential for ABL1 kinase sensitivity to imatinib (Gleevec) and dasatinib, and a specific mutation (T315I) has been observed in individuals with CML who develop imatinib or dasatinib resistance 23, 24 .
We therefore engineered the T315I gatekeeper mutation into each of 24 candidate dasatinib target kinases and introduced either wild-type or mutant kinases into GBM cells by lentiviral transduction. Expression of the kinases was documented using the Luminex assay (Supplementary Table 4 ). As expected, none of the 24 wild-type kinases conferred resistance to dasatinib in vitro (Fig. 3c) . Similarly, 22/24 of the mutant kinases failed to rescue dasatinib effects, indicating that they were not the relevant targets of dasatinib in this setting. In contrast, drug-resistant alleles of SRC and the SRC family member FYN rescued dasatinib effects (Fig. 3c) . We note, however, that whereas prominent phospho-SRC was detected by the Luminex assay and immunoblotting, phospho-FYN was not abundant in these cells (Fig. 2a, Supplementary Fig. 3b and Supplementary Table 6 ). Of note, we also tested 30 different anti-SRC short hairpin RNA constructs, none of which resulted in 450% reduction in phospho-SRC in T98G glioma cells (data not shown). This result probably reflects the cell's enormous plasticity in upregulating residual kinase activity in the face of attempted downregulation of a kinase on which the cell is dependent for survival.
The experiments described in this report demonstrate the feasibility and utility of a bead-based approach to profiling tyrosine kinase activity in cancer cells. In addition to recovering many of the known kinase activation events in cancer, we identified and validated SRC as a potential therapeutic target for GBM. Notably, the role of SRC in GBM was not suggested by recent DNA sequence or copy-number analysis 15 but required protein phosphorylation data for its discovery. Because dasatinib is administered orally and approved by the US Food and Drug Administration, it could proceed rapidly to testing in GBM clinical trials. More generally, the results described here support the case for undertaking large-scale efforts to generate comprehensive kinase activity profiles across the diversity of human cancers.
METHODS
Luminex immunosandwich assay. Individual bead-type of Luminex xMAP microspheres (Luminex) were coupled separately to capture antibodies against total tyrosine kinases using the following procedure. 100 ml microspheres were washed with 100 ml ddH 2 O and resuspended in 80 ml 100 mMNaH 2 PO 4 , pH 6.2. 10 ml 25 mg/ml Sulfo-NHS (Pierce) and 10 ml 25 mg/ml EDC (Pierce) were added and incubated at 25 1C for 20 min while shaking to activate the microspheres. The activated beads were washed with 250 ml 1Â PBS pH 7.4 twice and resuspended in 200 ml 1Â PBS. 20 mg capture antibodies in 50 ml 1Â PBS were added. The mixtures were incubated at 25 1C for 2 h while shaking in dark. The antibody-coupled beads were blocked with 500 ml PBS-TBN (0.02% Tween-20, 0.1% BSA and 0.05% NaN 3 in 1Â PBS pH7.4) at 25 1C for 30 min while shaking. Finally, the microspheres were washed with 500 ml PBS-TBN twice and stored in 500 ml PBS-TBN at 4 1C until use. 0.25 ml coupled microspheres per bead type were used for each sample. The microsphere mixture were transferred into a 96-well 1.2 mm filter plate (Millipore) and washed with 100 ml 1Â PBS plus 1% BSA pH 7.4 (Sigma) twice. 100 ml 1 mg/ml protein lysates were added to each well and incubated at 4 1C overnight while shaking. The microspheres were washed with 100 ml 1Â PBS plus 1% BSA pH 7.4 twice. 50 ml 4 mg/ml biotin-4G10 (UpState) were added and incubated at 25 1C for 30 min while shaking. The microspheres were then washed with 100 ml 1Â PBS plus 1% BSA pH 7.4 twice and then incubated with 50 ml 4 mg/ml R-phycoerythrin streptavidin conjugates (Molecular Probes) at 25 1C for 10 min. Finally, the samples were washed with 100 ml 1Â PBS plus 1% BSA pH 7.4 twice and resuspended in 50 ml 1Â PBS plus 1% BSA pH 7.4 for analysis.
The data were acquired with a Luminex 100 instrument (Luminex) according to manufacturer's instructions. The background readings for each capture antibody were obtained using microspheres incubated with 1Â cell lysis buffer (Cell Signaling Technology). Values were considered positive if they were threefold over the background and represented by log2-transformation of the folds over background. Negative values were threshold to -5. The preprocessed data were converted into .gct files and analyzed with GenePattern 3.0 (The Broad Institute).
Technical and biological variation. All analyses were based on median-based statistics. Variation was measured using the quartile coefficient of variation 25 , defined as: (Q 3 -Q 1 )/(Q 3 + Q 1 ), where Q 1 is the lower quartile and Q 3 is the upper quartile. To determine whether a tyrosine kinase was active or inactive in any given cell line, we evaluated its measured intensity against a reference as follows: (i) measure the tyrosine kinase in a reference where it is inactive. Repeat the measurement n times and note the observed intensity; (ii) let max be the maximum of these n measurements in the reference; (iii) for any new measurement of tyrosine kinase in any cell line, the tyrosine kinase is active if the new measurement exceeds max; the tyrosine kinase is otherwise inactive. With this procedure, the probability that a measurement greater than max could arise from an inactive tyrosine kinase depends on the value of n and can be calculated using the binomial distribution 26 .
Immunoprecipitation-liquid chromatography/tandem mass spectrometry (IP-LC/MS/MS). The basics of the procedure is as described 27 . Briefly, 2 Â 10 8 cells were lysed in 8 M urea/20 mM HEPES containing phosphatase inhibitors. Upon reduction of the disulfide bonds, the lysate was split into two aliquots and diluted with 20 mM HEPES to 2M or 0.5 M urea before digestion with trypsin or chymotrypsin, respectively. The total peptide mixtures were then desalted by Sep-Pak cartridge and resuspended in IP buffer, 50 mM MOPS/NaOH pH 7.2, 10 mM Na 2 PO 4 , 50 mM NaCl, along with four exogenous peptides containing phosphotyrosines added as controls. IP was performed with a cocktail of three protein-G agarose bead-bound phosphotyrosine antibodies pY100 (Cell Signaling), 4G10 (UpState) and PY99 (Santa Cruz Biotechnology) to enrich for phosphotyrosine-containing peptides. Peptides captured by phosphotyrosine antibodies were eluted under basic followed by acidic conditions. The IP eluate was analyzed by data-dependent LC-MS/MS using a Thermo LTQ-FT instrument. Each peptide's site(s) of phosphorylation were uniquely mapped using the sequence information present in its ion trap MS/MS spectrum, unless it had several tyrosine residues and fragmented poorly. All MS and MS/MS data was processed using the Spectrum Mill software package (Agilent Technologies).
Dasatinib treatment, viability, proliferation, migration and apoptosis assays. Human glioblastoma T98G cells cultured in 96-well plates (1,000 cells/well) were treated with different concentrations of dasatinib and a vehicle control (DMSO). Dasatinib 16 was synthesized by the Chemical Biology Program at the Broad Institute. Treatments lengths varied from 24 h for migration and proliferation assays to 48 h for apoptosis and 96 h for viability. Cell viability was determined by quantification of ATP present in culture using CellTiter-Glo (Promega). Cell proliferation was determined by incorporation of BrdU to actively proliferating cells and subsequent quantification of BrdU by immunoassay (Calbiochem). The kit's substrate solution was replaced with Glo Substrate (R&D) for higher sensitivity. CytoSelect Cell Migration Assay Kit (Cell Biolabs) was used to assess cell migration. Migratory cells were detected using CellTiter-Glo instead of the dye provided with the kit. Apoptosis was determined using a luminescence assay that quantifies caspases 3 and 7 activities (Caspase Glo 3/7 Assay, Promega).
Orthotropic glioblastoma model. Orthotopic glioma xenografts were established as previously described 28 . Briefly, 50,000 U87-LucNeo cells were stereotactically implanted into the right brain of 6-week-old male NCr nude mice using a 1:1 mix of propylene glycol and water as the vehicle. Bioluminescence imaging was performed 7 and 12 d after tumor implantation to identify mice with logarithmically growing tumors. Mice were divided into treatment groups with statistically equivalent mean bioluminescence. Treatments consisted of either imatinib at 75 mg/kg twice a day by oral gavage, dasatinib at 10 mg/kg twice a day by oral gavage, or vehicle. Tumor burden was assessed by bioluminescence imaging as previously described, and for each individual animal, values were expressed relative to the bioluminescence at the start of treatment. All animal studies were performed under an IACUC approved protocol. Table 10 and inserted into pENTR/D-TOPO (Invitrogen). Site-directed mutagenesis was performed with the primers listed in Supplementary Table 10 according to manufacturer's recommendations (Stratagene). Both wild-type and mutant constructs were sequence verified. LR recombination reaction into pLenti6/UbC/V5-DEST vector was done according to Invitrogen's guideline. The inserts were verified again with sequencing. Transfections. 293-FT producer cells (Invitrogen) were transfected using ViraPower Lentiviral Expression Systems (Invitrogen) according to manufacturer's protocol. Virus was harvested at 48 h and 72 h. Infections. Cells were plated in 96-well plates (1,000 cells/well) and infected with 10 ml of wild-type and mutant tyrosine kinase lentivirus. Infections were done in triplicates. On day 2, cells were treated with various concentrations of dasatinib. Viability was assessed at 96 h after dasatinib treatment.
Accession code. Tyrosine phosphorylation data for diverse human cancers are available at http://www.ncbi.nlm.nih.gov/geo under the accession number GSE13808.
Note: Supplementary information is available on the Nature Biotechnology website.
